QScreen AI Inc. News Releases

QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability

Mon, 20 Jul 2026 07:01:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated...

QScreen AI Secures Second US Patent, Extending Single-Camera Impairment Detection on Standard Hardware

Tue, 14 Jul 2026 07:02:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection method, after the United States Patent and Trademark Office granted the Company US Patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026. The new grant extends the Company's protection to impairment detection from a single camera on...

QScreen AI Announces Adoption of Semi-Annual Reporting

Fri, 26 Jun 2026 07:02:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").Introduced by the...

QScreen AI Announces Close of First Tranche of Private Placement

Thu, 25 Jun 2026 07:01:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement.The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement...

QScreen AI Launches European Investor Roadshow Following Recent Strategic and Technology Milestones

Mon, 01 Jun 2026 07:03:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 1, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announced that members of its senior leadership team will participate in a five-city investor roadshow across Central Europe from June 1 to June 5, 2026.DateCity June 1Munich, Germany June 2Ljubljana, Slovenia June 3Budapest, Hungary June 4Bratislava, Slovakia June 5Vienna, Austria Advancing Platform...

QScreen AI Appoints Former Pentagon Joint Artificial Intelligence Center Director Lt. Gen. Michael S. Groen (Ret.) to Advisory Board Following Live Platform Demonstration

Tue, 19 May 2026 07:03:00 -0400

Former US Department of Defense AI leader joins QScreen AI after reviewing the platform in person to support institutional commercialization efforts across North America Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announces the appointment of Lieutenant General Michael S. Groen (Ret.) to its Advisory Board. Lt. Gen. Groen is the former Director of the Joint...

QScreen AI Integrates Passive Voice Analysis into Multi-Signal Screening Platform - System Now Reads Physiological, Acoustic, and Behavioral Signals Simultaneously in Real Time

Wed, 06 May 2026 07:03:00 -0400

Individual voice baseline established on first encounter, deviation measured on every return visit; no additional hardware required; platform now fully integrated across all three signal modalities Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen"), today announced the full integration of a novel voice analysis engine into its multi-signal screening platform, expanding the system from camera and structured clinical intake into...

QScreen AI Reports Internal Validation Results for Correctional Intake Platform: 100% Sensitivity on Suicide Risk and Withdrawal Detection Across 65 Calibrated Clinical Scenarios

Mon, 04 May 2026 07:03:00 -0400

Nine instruments validated against published standards including Columbia C-SSRS, CIWA-Ar, and COWS; paper-only workflow showed materially lower detection rates across the same scenarios; 60-day live pilot structured and ready Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening today reports internal validation results for its correctional intake platform across 65...

QScreen AI Appoints Former Union Pacific Vice President as Strategic Advisor to Drive Expansion into North American Rail and Transportation Markets

Wed, 29 Apr 2026 07:03:00 -0400

Veteran rail executive with 25 years of senior commercial relationships across North America's Class I railroads joins a platform that enables real-time identification of probable drug use from a camera without requiring blood, breath, or urine testing.Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today announces the appointment of José Humberto "Beto"...

QScreen AI Completes Platform That Identifies Probable Drug a Person Has Consumed in Real Time from a Camera Alone - Targets Correctional Facilities Facing Coroner Scrutiny over Withdrawal Deaths

Mon, 27 Apr 2026 06:53:00 -0400

Patent-protected QAI Platform identifies the probable drug class - alcohol, opioids, benzodiazepines, stimulants, or cannabis from physiological camera data and simultaneously administers CIWA-Ar, COWS, C-SSRS and 10 further validated clinical instruments in under seven minutes with no hardware and no IT project; former Director of Pentagon Joint Artificial Intelligence Center advancing commercial engagement across US correctional facilities and national defense installations; Canadian...